Fulgent Genetics (FLGT) Net Equity Issued and Repurchased (2019 - 2021)

Fulgent Genetics has disclosed Net Equity Issued and Repurchased across 3 years of filings, most recently posting $13.8 million for Q4 2021.

• In Q4 2021, Net Equity Issued and Repurchased fell 93.21% year-over-year to $13.8 million; the TTM figure through Dec 2021 stood at $89.5 million (down 63.66% YoY), while the FY2021 annual figure was $89.5 million, down 63.66% from the prior year.
• Net Equity Issued and Repurchased came in at $13.8 million for Q4 2021 at Fulgent Genetics, up from -$30000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $203.9 million in Q4 2020 to a low of -$130000.0 in Q1 2020.
• Average Net Equity Issued and Repurchased over 3 years is $40.4 million, with a median of $27.6 million recorded in 2019.
• The largest YoY upside for Net Equity Issued and Repurchased was 36859.23% in 2021 against a maximum downside of 100.07% in 2021.
• Over 3 years, Net Equity Issued and Repurchased stood at $27.6 million in 2019, then jumped by 637.48% to $203.9 million in 2020, then sank by 93.21% to $13.8 million in 2021.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $13.8 million in Q4 2021, -$30000.0 in Q3 2021, and $27.9 million in Q2 2021.